Total Payments
$1.6M
2024 Payments
$224,709
Companies
13
Transactions
129
Medicare Patients
54
Medicare Billing
$2,732
Payment Breakdown by Category
Consulting$1.5M (96.7%)
Other$24,000 (1.5%)
Travel$13,095 (0.8%)
Research$12,997 (0.8%)
Food & Beverage$1,566 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.5M | 44 | 96.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,000 | 3 | 1.5% |
| Travel and Lodging | $13,095 | 46 | 0.8% |
| Unspecified | $12,997 | 14 | 0.8% |
| Food and Beverage | $1,566 | 22 | 0.1% |
Payments by Type
General
$1.6M
115 transactions
Research
$12,997
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $1.3M | 36 | $0 (2024) |
| PFIZER INC. | $136,095 | 14 | $0 (2023) |
| Novartis Pharma AG | $50,309 | 28 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23,681 | 9 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $15,217 | 15 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,293 | 7 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $5,040 | 1 | $0 (2020) |
| CSL Behring | $4,586 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $3,967 | 8 | $0 (2017) |
| Novo Nordisk Inc | $1,350 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $224,709 | 9 | Alnylam Pharmaceuticals Inc. ($220,890) |
| 2023 | $243,005 | 19 | Alnylam Pharmaceuticals Inc. ($222,059) |
| 2022 | $228,652 | 8 | Alnylam Pharmaceuticals Inc. ($220,241) |
| 2021 | $240,415 | 11 | Alnylam Pharmaceuticals Inc. ($220,004) |
| 2020 | $252,468 | 9 | Alnylam Pharmaceuticals Inc. ($226,733) |
| 2019 | $266,855 | 24 | Alnylam Pharmaceuticals Inc. ($215,960) |
| 2018 | $108,497 | 31 | PFIZER INC. ($75,000) |
| 2017 | $14,499 | 18 | Novartis Pharma AG ($8,729) |
All Payment Transactions
129 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $13,333.33 | General |
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Dividend, profit or other return on investment | $199,834.12 | General |
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $591.95 | General |
| 12/03/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $73.07 | General |
| 09/16/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $316.95 | General |
| 09/16/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $73.79 | General |
| 03/29/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $6,666.67 | General |
| 03/06/2024 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $2,469.43 | Research |
| Study: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 02/22/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/29/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $13,333.33 | General |
| 12/07/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Dividend, profit or other return on investment | $199,796.70 | General |
| 12/07/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $433.90 | General |
| 12/07/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $36.63 | General |
| 12/07/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $34.61 | General |
| 12/07/2023 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $10.44 | General |
| 12/05/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $697.61 | General |
| 11/29/2023 | Novartis Pharma AG | ENTRESTO (Drug), ILARIS | Consulting Fee | Cash or cash equivalent | $11,550.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/13/2023 | Novartis Pharma AG | ENTRESTO (Drug), ILARIS | Travel and Lodging | In-kind items and services | $214.91 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/13/2023 | Novartis Pharma AG | ENTRESTO (Drug), ILARIS | Travel and Lodging | In-kind items and services | $69.52 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/22/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $346.61 | General |
| 08/22/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $165.40 | General |
| 08/22/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $76.00 | General |
| 03/31/2023 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $6,666.67 | General |
| 03/07/2023 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $138.99 | General |
| 03/06/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $2,123.45 | Research |
| Study: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS • Category: CARDIOVASCULAR AND METABOLISM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $7,147 | 8 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $5,314 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN EVERY FOUR WEEKS TREATMENT REGIMEN OF ALIROCUMAB IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $535.14 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 35 | 35 | $3,281 | $1,381 |
| 2022 | 1 | 19 | 21 | $3,075 | $1,351 |
Total Patients
54
Total Services
56
Medicare Billing
$2,732
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 12 | $1,835 | $705.05 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 12 | $1,116 | $602.36 | 54.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 11 | 11 | $330.00 | $73.92 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 21 | $3,075 | $1,351 | 43.9% |
About Dr. Daniel Rader, MD
Dr. Daniel Rader, MD is a Internal Medicine healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316979610.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Rader, MD has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $224,709 received in 2024. These payments were reported across 129 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($1.5M).
As a Medicare-enrolled provider, Rader has provided services to 54 Medicare beneficiaries, totaling 56 services with total Medicare billing of $2,732. Data is available for 2 years (2022–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Philadelphia, PA
- Active Since 07/07/2006
- Last Updated 12/08/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1316979610
Products in Payments
- ENTRESTO (Drug) $22,504
- LCZ696 (Drug) $20,310
- ILARIS (Biological) $16,713
- EVKEEZA (Biological) $9,367
- LCZ696_ENTRESTO_CARDIOVASCULAR (Drug) $7,495
- PRALUENT ALIROCUMAB INJECTION (Biological) $4,197
- PELACARSEN (Drug) $3,935
- MK0859 (Drug) $2,750
- PRALUENT (Biological) $1,653
- LEQVIO (Drug) $1,550
- MK-0859 (Drug) $598.59
- ZYBAN (Drug) $49.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Philadelphia
Pitamber Devgon, Md, MD
Internal Medicine — Payments: $7.5M
Internal Medicine $7.5M
Dr. David Horn, M.d, M.D
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Corey Langer, Md, MD
Internal Medicine — Payments: $742,647
Internal Medicine $742,647
Dr. Intekhab Ahmed, M.d, M.D
Internal Medicine — Payments: $621,997
Internal Medicine $621,997
David Goldmann, Md, MD
Internal Medicine — Payments: $587,696
Internal Medicine $587,696
Michael Kochman, Md, MD
Internal Medicine — Payments: $401,750
Internal Medicine $401,750